key: cord-0849262-cieh5gyp
authors: Rose, Deja R; Mahadeen, Ahmad Z; Carlson, Alise K; Planchon, Sarah M; Sedlak, Jennifer; Husak, Scott; Bermel, Robert A; Cohen, Jeffrey A; Moss, Brandon P
title: Clinical features and outcomes of COVID-19 despite SARS-CoV-2 vaccination in people with multiple sclerosis
date: 2021-11-26
journal: Mult Scler J Exp Transl Clin
DOI: 10.1177/20552173211057110
sha: 4a9732126ce94b97f6f7c87279c0126ad2717213
doc_id: 849262
cord_uid: cieh5gyp

BACKGROUND: Several studies have demonstrated reduced serological response to vaccines in patients treated with anti-CD20 agents. However, limited data exist surrounding the clinical effect of disease modifying therapy (DMT) use on vaccine efficacy. OBJECTIVES: To investigate breakthrough coronavirus disease 2019 (COVID-19) in vaccinated people with multiple sclerosis (PwMS) on DMT. METHODS: PwMS on DMT diagnosed with COVID-19 after full vaccination were identified from an existing Cleveland Clinic COVID-19 registry, supplemented by provider-identified cases. Demographics, disease history, DMTs, comorbidities, exposures, vaccination status, and COVID-19 outcomes were confirmed by review of the electronic medical record. RESULTS: Thirteen (3.8%) of 344 fully vaccinated people with multiple sclerosis on disease modifying therapy were diagnosed with COVID-19 after vaccination. Ten patients (76.9%) were on an anti-CD20 therapy, the remaining 3 (23.1%) on fingolimod. Only 2 patients (15.4%), both on anti-CD20 therapy, required hospitalization and steroid treatment. Neither required Intensive Care Unit admission. CONCLUSION: Patients treated with anti-CD20 agents and sphingosine 1-phosphate receptor modulators may still be at risk for COVID-19 despite vaccination. While still at risk for hospitalization, intubation and death from COVID-19 appear rare. Larger studies analyzing how this may differ in the setting of emerging variants are needed.

Three vaccines for coronavirus disease 2019 (COVID-19) were approved in the United States under emergency use authorization; reported efficacies included 95% (Pfizer/BNT162b2), 94% (Moderna/ mRNA-1273) and 67% (Janssen/Ad26.COV2.S) in preventing infection. 1 A systematic review of COVID-19 in people with multiple sclerosis (PwMS) estimated the pooled prevalence to be higher than the general population at 4%, with 10% of cases requiring hospitalization. 2 A separate review found that nearly half of COVID-19 cases in PwMS were in the setting of anti-CD20 therapy, raising concern for increased risk of COVID-19 in PwMS on disease-modifying therapy (DMT), and particularly in those on anti-CD20 agents. 3 Subsequent studies demonstrated a reduced serological response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in PwMS on anti-CD20 and sphingosine 1-phosphate receptor modulator (S1PR) DMTs. [4] [5] [6] Given these results, questions remained regarding which factors were most important for developing immunity, and how reduced serological vaccine response translated to clinical outcomes. In this study, we investigated breakthrough COVID-19 in fully vaccinated PwMS. either confirmed (for existing registry patients) or abstracted (for provider-identified cases) by review of the electronic medical record.

We Comparative demographics between those with and without breakthrough COVID-19 are summarized in Table 1 . Comprehensive COVID-19 outcomes are in Table 2 . Only two (15.4%) of the 13 patients required hospitalization; Both were on anti-CD20 therapy. One stayed three days, and the other stayed 13 days after the development of pneumonia. Neither required intensive care unit (ICU) admission or mechanical ventilation; both were discharged home. Both received steroid treatment, and the patient with pneumonia was additionally treated with remdesivir. Another patient, also on anti-CD20 treatment, developed pneumonia but was managed as an outpatient on inhaled corticosteroids. The three patients on fingolimod did not require COVID-targeted treatment or hospitalization. The times from last infusion to first vaccination were similar for patients on anti-CD20 therapy with breakthrough infection compared to those without, median 119 days; interquartile range (95-133) versus 137; interquartile range (95-152), respectively.

Prior pre-vaccination studies estimated the prevalence of COVID-19 in PwMS to be 4%. Although of limited sample size, our post-vaccination prevalence occurred exclusively in PwMS on DMT and was similar at 3.8%, suggesting that the 67%-95% reported vaccine efficacy may not fully apply to this population. Despite disease breakthrough, our patients had good outcomes. Most did not require hospitalization or COVID-19 treatment, none required ICU admission and none died.

In line with prior reports of reduced response to inactivated viral vaccines and higher breakthrough COVID-19 infections, particularly in those on anti-CD20 and S1PR DMTs, all observed breakthrough infections occurred in this subpopulation. However, in contrast to a report of lower humoral immunity in those on an S1PR modulator compared to anti-CD20, 22.7% and 3.8%, respectively, 6 and limited by the absence of available SARS-CoV-2 antibody titers from our patients, those requiring hospitalization in our study were all on anti-CD20 therapy. Such discrepancy highlights the range of anti-SARS-CoV-2 immune response and the remaining uncertainty surrounding which aspects of protective immunity translate to more favourable clinical outcomeshumoral versus cell-mediated processes. Recent data suggest patients on anti-CD20 have a preserved T-cell response to vaccination, albeit with shifts in lymphocyte subpopulations, 8 ,9 yet these patients remain at higher risk for clinically significant breakthrough. Larger studies are required to analyze the range of vaccine response on DMT and if breakthrough COVID-19 outcomes differ in the setting of emerging variants. Nevertheless, PwMS on anti-CD20 and S1PR therapies appear at higher risk for breakthrough disease. Although still at risk for hospitalization, intubation and death from COVID-19 appear rare.

Bermel has served as a consultant for

COVID-19 vaccines: A review of the safety and efficacy of current clinical trials

The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): a systematic review and meta-analysis

Experience in multiple sclerosis patients with COVID-19 and diseasemodifying therapies: A review of 873 published cases

COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by

Negative SARS-CoV2-antibodies after positive COVID-19-PCR nasopharyngeal swab in patients treated with anti-CD20 therapies

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with highefficacy disease-modifying therapies

Development and validation of a model for individualized prediction of hospitalization risk in 4,536 patients with COVID-19

Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy

Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy

The authors thank our patients for participating in the registry, Mellen Center clinicians for referring patients, and Mellen Center research and intake staff for providing technical support for the study. 

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or Funding The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: S.M. Planchon received researching funding from Guthy Jackson Charitable Foundation. He receives ongoing research support directed to his institution from Biogen, Genentech and Novartis. J.A. Cohen received personal compensation for consulting for Biogen, Bristol-Myers Squibb, Convelo, Genentech, Janssen, NervGen, Novartis and PSI; speaking for H3